Glp-1 enhancers
By combining natural plant and fungal extracts, this product addresses the issues of side effects and poor compliance associated with existing nutritional supplements, effectively controlling weight, reducing appetite and calorie intake, lowering blood sugar spikes, and improving bioavailability.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- PM INT
- Filing Date
- 2025-08-29
- Publication Date
- 2026-06-19
AI Technical Summary
Existing nutritional supplements have problems such as side effects, poor compliance, low bioavailability, and high cost in terms of weight control, appetite reduction, satiety, and calorie reduction, and there is a lack of natural plant and fungal alternatives.
This product utilizes a combination of natural plant and fungal extracts containing DPP-4 inhibitors, GLP-1 analogs, and GLP-1 secretion promoters, including ingredients such as dandelion, white mulberry, bitter melon, and brewer's yeast. It is administered orally as a nutritional supplement to promote the physiological effects of the GLP-1 axis.
It achieves the effects of weight control, appetite reduction, satiety, calorie reduction, and lowering blood glucose peaks, while avoiding the side effects of synthetic drugs and improving bioavailability and compliance.
Abstract
Description
Technical Field
[0001] This application relates to a composition that can be used as a nutritional supplement or nutrient and its uses. Background Technology
[0002] With increased production and supply of nutrients, living conditions have improved for most of the population. However, undesirable effects, such as obesity, have also emerged. Some people affected by obesity perceive it negatively solely for visual or emotional reasons. Therefore, there has long been a demand for medications used to control weight, reduce appetite, induce satiety, and decrease calorie intake.
[0003] To meet this need, several agents have been developed, including nutritional supplements, but there is still room for improvement.
[0004] In response to food intake, two peptide hormones, glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1), are released from the intestine. They have a direct stimulatory effect on pancreatic β-cells and increase insulin secretion. It is generally known that oral glucose intake triggers higher insulin secretion than intravenous delivery—a phenomenon known as the "incretin effect."
[0005] The physiological effects of GLP-1 include glucose-dependent insulin secretion stimulation and thus lowering blood glucose levels, inhibition of glucagon secretion and thus inhibiting glycogenolysis, inhibition of gastric emptying and thus enhancing satiety, inhibition of food intake, and reduction of appetite and weight loss.
[0006] In recent years, a number of substances have been developed that can be used as antidiabetic agents and / or for weight management, specifically targeting the GLP-1 axis, in the form of GLP-1 receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors (enzymes responsible for the rapid inactivation of GLP-1 in the bloodstream). Examples of GLP-1 receptor agonists include semaglutide (Ozempic, Ribelsus, Wegovy) and liraglutide (Saxenda, Victoza).
[0007] However, these substances, as well as long-known nutritional supplements, have drawbacks such as side effects, poor adherence, low bioavailability, weak efficacy, and / or high cost. There is also a need for natural-based alternatives, particularly those based on plants and / or fungi.
[0008] Against this backdrop, one object of this application is to provide a composition that overcomes the shortcomings of the prior art. In particular, the composition preferably has at least one of the following effects: i) weight control, ii) reduced appetite, iii) producing a feeling of fullness, and iv) reduced calorie intake. Summary of the Invention
[0009] To achieve the above objectives, in a first aspect, a composition is provided comprising: i) DPP-4 inhibitors selected from dandelion (Taraxacum officinale) extract, white mulberry (Morus alba) extract, bitter melon (Momordica charantia) extract, Saccharomyces cerevisiae hydrolysate, garlic (Allium sativum) extract, grape (Vitis vinifera) extract, turmeric (Curcuma longa) extract, moringa (Moringa oleifera) extract, and fenugreek (Trigonella foenum-graecum) extract; and ii) GLP-1 analogues selected from Saccharomyces cerevisiae hydrolysate, Morus alba extract, Ilex paraguariensis extract, Coffea arbica extract, Portulaca oleracea extract, Momordica charantia extract, Lagerstroemia speciosa extract, Malus domestica extract, Cinnamomum verum extract, and Trigonella foenum-graecum extract; and iii) GLP-1 secretion promoters, selected from inulin, gum arabic, bitter melon (Momordica charantia) extract, purslane (Portulaca oleracea) extract, Berberis vulgaris extract, Arabica coffee (Coffea arabica) extract, Angelica dahurica extract, turmeric (Curcuma longa) extract, and Trigonella foenum-graecum extract. At least one ingredient was selected from each of groups i) to iii), and a total of at least three different ingredients were selected.
[0010] To achieve the above objectives, a composition is also provided, optionally according to the first aspect, comprising dandelion extract, brewer's yeast hydrolysate, and bitter melon extract.
[0011] To achieve the above objectives, a composition is also provided, optionally according to the first aspect, comprising dandelion extract, white mulberry extract and bitter melon extract.
[0012] To achieve the above objectives, a capsule is also provided, comprising a capsule shell and the composition according to this application, wherein the capsule shell comprises a cellulose ether.
[0013] The concept upon which this application is based is to provide a combination of at least three substances based on natural materials, particularly plants and / or fungi, including a DPP-4 inhibitor, a GLP-1 analog, and a GLP-1 secretion promoter. This combination of components can cause at least one of the following effects: i) weight control, ii) reduced appetite, iii) a feeling of fullness, iv) reduced calorie intake, and v) reduced glycemic spikes. According to this application, a GLP-1 analog is a substance that has similar physiological effects to GLP-1 but does not directly activate the GLP-1 receptor, representing a distinguishing feature from synthetic GLP-1 receptor agonists.
[0014] The subject of this application is also the use of the composition and / or capsules according to this application to achieve at least one of the following effects: i) weight control, ii) appetite reduction, iii) satiety, iv) calorie reduction and v) reduction of blood glucose peak.
[0015] The subject of this application is also a method for achieving at least one of the following effects: i) controlling weight, ii) reducing appetite, iii) producing a feeling of fullness, iv) reducing calorie intake and v) reducing blood glucose peaks, wherein the composition and / or capsules according to this application are taken orally. Detailed Implementation
[0016] The composition is preferably a nutritional supplement and / or nutrient.
[0017] The composition preferably comprises dandelion (Taraxacum officinale) extract. The dandelion extract is preferably an extract of dandelion leaves. It is preferably a dry extract, and preferably has a herb-extract ratio of 3:1 to 5:1. It has been determined that dandelion extract can act as a DPP-4 inhibitor, and particularly in the combination according to this application, it can contribute to achieving the aforementioned effects.
[0018] The composition preferably comprises a bitter melon (Momordica charantia) extract. The bitter melon extract is preferably an extract derived from the fruit of the bitter melon. It is preferably a dry extract. The extract preferably contains at least 5 wt.% bitter substances, for example, 5 wt.% to 15 wt.% bitter substances, relative to the total weight of the dry extract. It has been determined that the bitter melon extract can act as a DPP-4 inhibitor, a GLP-1 analog, and a GLP-1 secretion promoter, and particularly in the combination according to this application, it can be used to achieve the aforementioned effects.
[0019] The composition preferably comprises a hydrolysate of *Saccharomyces cerevisiae*. The *Saccharomyces cerevisiae* hydrolysate is preferably a high-peptide hydrolysate. In this high-peptide hydrolysate, the peptides can be concentrated to <10,000 Da, such that the hydrolysate consists of about 60 wt.% protein and about 33 wt.% carbohydrates. It has been determined that yeast hydrolysate can act as a DPP-4 inhibitor and a GLP-1 analog, and particularly in the combination according to this application, it can help achieve the desired effect.
[0020] The composition preferably comprises a purslane (Portulaca oleracea) extract. The purslane extract is preferably an extract from the aerial parts of the purslane plant. It is preferably a dry extract, and preferably has a herb-extract ratio of 3:1 to 5:1. It has been determined that the purslane extract can act as a GLP-1 analog and a GLP-1 secretion promoter, and particularly in the combination according to this application, it can help achieve the desired effects.
[0021] The composition preferably contains a bioenhancer. Bioenhancers can improve the bioavailability of orally administered substances. Due to the presence of one or more bioenhancers, the composition according to this application can implement the nutrient transport concept (NTC). The bioenhancer is preferably a ginger (Zingiber officinale) extract. In other words, the composition preferably contains a ginger extract. Preferably, the ginger extract is an extract of ginger rhizome. It is preferably a dry extract, preferably having a herb-extract ratio of 3:1 to 5:1. The extract is preferably a CO2 extract.
[0022] The composition preferably contains zinc, preferably zinc gluconate.
[0023] The composition preferably includes a filler, preferably selected from gum arabic and inulin and mixtures thereof. Gum arabic and inulin may have a high proportion of fiber, which acts as dietary fiber. For example, gum arabic derived from the Acacia genus and having CAS number 9000-01-5 is suitable. It has been determined that gum arabic and inulin can act as GLP-1 secretion promoters, and particularly in the combination according to this application, can help achieve the desired effect.
[0024] The composition preferably comprises an extract of white mulberry (Morus alba). The white mulberry extract is preferably an extract derived from the leaves of the white mulberry. It is preferably a dry extract, and preferably contains about 1.5 wt.% to 5 wt.% 1-deoxynojirimycin (1-DNJ) relative to the total weight of the dry extract. It has been determined that the white mulberry extract can act as a DPP-4 inhibitor and a GLP-1 analog, and particularly in the combination according to this application, it can contribute to achieving the aforementioned effects.
[0025] In a preferred embodiment, the composition comprises a Berberis vulgaris extract. The Berberis vulgaris extract is preferably an extract derived from the fruit of the Berberis vulgaris. It is preferably a dry extract, and preferably has a berberine content of at least 1 wt.%, for example, from 1 wt.% to 3 wt.%, relative to the total weight of the dry extract. It has been determined that the Berberis vulgaris extract can act as a GLP-1 secretion promoter, and particularly in the combination according to this application, it can help achieve the desired effect.
[0026] In a preferred embodiment, the composition comprises an Arabica coffee (Coffea arabica) extract. The Arabica coffee extract is preferably an extract derived from Arabica green coffee beans. It is preferably a dry extract, preferably having a herb-extract ratio of 8:1 to 14:1. The extract preferably contains at least 35 wt.% to 55 wt.% chlorogenic acid and 2 wt.% to 7 wt.% caffeine relative to the total weight of the dry extract. The extractant used to prepare the extract can be a mixture of ethanol and water, such as a mixture of 80% ethanol and 20% water, wherein the extractant is evaporated after extraction to obtain a dry extract. This also applies to the extractants and methods used in other extracts disclosed herein. It has been determined that the Arabica coffee extract can act as a GLP-1 analog and a GLP-1 secretion promoter, and particularly in the combination according to this application, it can contribute to achieving the aforementioned effects.
[0027] In a preferred embodiment, the composition comprises an extract of *Ilex paraguariensis*. The *Ilex paraguariensis* extract is preferably an extract from the leaves of *Ilex paraguariensis*. It is preferably a dry extract, and preferably has a caffeine content of about 0.5 wt.% to 5 wt.% relative to the total weight of the dry extract. The extractant used to prepare this extract may consist of water. It has been determined that the *Ilex paraguariensis* extract can act as a GLP-1 analog, and particularly in the combination according to this application, it can contribute to achieving the aforementioned effects.
[0028] In a preferred embodiment, the composition comprises: Dandelion extract; White mulberry extract; Bitter melon extract; brewer's yeast hydrolysate; Paraguayan wintergreen extract; Arabica coffee extract; Purslane extract; The filler is selected from gum arabic and inulin and mixtures thereof; Ginger extract; and Zinc gluconate. It has been determined that the combination according to this application is suitable for achieving at least one of the following effects: i) weight control, ii) appetite reduction, iii) satiety, iv) calorie reduction, and v) reduction of blood glucose peak.
[0029] In another preferred embodiment, the composition comprises Dandelion extract; White mulberry extract; Bitter melon extract; brewer's yeast hydrolysate; Berberis extract; Purslane extract; Fillers selected from gum arabic and inulin and mixtures thereof; Ginger extract; and Zinc gluconate. It has been determined that the combination according to this application is suitable for achieving at least one of the following effects: i) weight control, ii) appetite reduction, iii) satiety, iv) calorie reduction, and v) reduction of blood glucose peak.
[0030] The capsule shell according to this application contains a cellulose ether. The cellulose ether preferably includes hydroxypropyl methylcellulose.
[0031] The intended use according to this application is preferably for non-medical purposes, particularly as a nutritional supplement and / or nutrient. In the intended use according to this application, it is preferred to take the composition or capsule orally before meals, preferably 5 to 60 minutes before meals. Preferably, the composition or capsule is taken orally three times daily. The composition may also be divided into multiple capsules. For example, two capsules may be taken by a healthy person before breakfast, lunch, and dinner.
[0032] In a preferred embodiment according to the use of this application, the medication is administered orally daily: 0.01g to 0.2g of dandelion extract; 0.01g to 0.5g of white mulberry extract; 0.05g to 0.5g of bitter melon extract; 0.25g to 1.0g of brewer's yeast hydrolysate; 0.05g to 0.5g of Paraguayan holly extract; 0.1g to 0.5g of Arabica coffee extract; 0.01g to 0.5g of purslane extract; 0.5g to 5g of filler, selected from gum arabic and inulin and mixtures thereof; 0.001g to 0.01g of ginger extract; and 0.001g to 0.05g of zinc gluconate.
[0033] In another preferred embodiment according to the use of this application, it is administered orally daily: 0.01g to 0.2g of dandelion extract; 0.01g to 0.5g of white mulberry extract; 0.05g to 0.5g of bitter melon extract; 0.25g to 1.0g of brewer's yeast hydrolysate; 0.01g to 0.2g of Berberis thunbergii extract; 0.01g to 0.5g of purslane extract; 0.5g to 5g of filler, selected from gum arabic and inulin and mixtures thereof; 0.001g to 0.01g of ginger extract; and 0.001g to 0.05g of zinc gluconate.
[0034] The method according to this application is preferably a non-medical method. Statements regarding the use of this application are applicable herein.
[0035] The implementation schemes described herein can be combined with each other in any desired manner, provided that no contrary result is clearly derived from the description of the subject matter and implementation schemes.
[0036] The verbs “to contain” and “to include” and their conjugations also include the verbs “to consist of” and their conjugations.
[0037] This application is described below based on embodiments, which are not intended to be limiting.
[0038] Example 1 Capsules #00 are filled with the composition such that each capsule contains: 0.017g of dandelion leaf extract; 0.067g of bitter melon fruit extract; 0.083g of brewer's yeast hydrolysate; The remainder is gum arabic.
[0039] The capsule shell contains hydroxypropyl methylcellulose.
[0040] Example 2 Capsules #00 are filled with the composition such that each capsule contains: 0.017g of dandelion leaf extract; 0.050g of white mulberry extract; 0.067g of bitter melon fruit extract; The remainder is gum arabic.
[0041] The capsule shell contains hydroxypropyl methylcellulose.
[0042] Example 3 Capsules #00 are filled with the composition such that each capsule contains: 0.017g of dandelion leaf extract; 0.050g of white mulberry extract; 0.067g of bitter melon fruit extract; 0.083g of brewer's yeast hydrolysate; 0.013g of Paraguayan holly leaf extract; Extract of 0.050g of Arabica green coffee beans; 0.030g of extract from the aerial parts of purslane; 0.2g gum arabic; 0.001g of ginger rhizome extract; and 0.002g of zinc gluconate.
[0043] The capsule shell contains hydroxypropyl methylcellulose.
[0044] Example 4 Capsules #00 are filled with the composition such that each capsule contains: 0.017g of dandelion leaf extract; 0.050g of white mulberry extract; 0.067g of bitter melon fruit extract; 0.083g of brewer's yeast hydrolysate; 0.017g of Berberis thunbergii extract; 0.030g of extract from the aerial parts of purslane; 0.2g gum arabic; 0.001g of ginger rhizome extract; and 0.002g of zinc gluconate.
[0045] Example 5 Healthy subjects took two capsules according to Examples 1-4 each time for an extended period, 30 minutes before breakfast, lunch, and dinner.
[0046] In at least a subset of subjects, the administration produced at least one of the following effects: better weight control, reduced appetite and calorie intake, and a feeling of fullness.
Claims
1. A composition comprising: i) DPP-4 inhibitors, selected from dandelion extract, white mulberry extract, bitter melon extract, brewer's yeast hydrolysate, garlic extract, grape extract, turmeric extract, moringa extract and fenugreek extract. ii) GLP-1 analogues selected from Saccharomyces cerevisiae hydrolysate, white mulberry extract, Paraguayan holly extract, Arabica coffee extract, purslane extract, bitter melon extract, Lagerstroemia indica extract, apple extract, Ceylon cinnamon extract, and fenugreek extract; and iii) GLP-1 secretion enhancer, selected from inulin, gum arabic, bitter melon extract, purslane extract, prickly ash extract, Arabica coffee extract, angelica dahurica extract, turmeric extract, and fenugreek extract. wherein At least one ingredient was selected from each of groups i) to iii), and a total of at least three different ingredients were selected.
2. The composition of claim 1, comprising: Dandelion extract; Bitter melon extract; and Brewing yeast hydrolysate.
3. A composition according to any preceding claim, wherein, The composition contains purslane extract.
4. A composition according to any preceding claim, wherein, The composition contains a bio-enhancer.
5. A composition according to any one of the preceding claims, wherein The composition contains ginger extract.
6. A composition according to any one of the preceding claims, wherein The composition contains zinc, preferably zinc gluconate.
7. A composition according to any one of the preceding claims, wherein The composition contains gum arabic.
8. A composition according to any one of the preceding claims, wherein The composition contains white mulberry extract.
9. A composition according to any one of the preceding claims, wherein, The composition contains berberis extract.
10. A composition according to any one of the preceding claims, wherein The composition contains Arabica coffee extract.
11. The composition according to any one of the preceding claims, characterized in that, The composition contains Paraguayan wintergreen extract.
12. The composition according to any one of the preceding claims, characterized in that, The composition contains inulin.
13. A capsule comprising a capsule shell and a composition as described in any one of the preceding claims, wherein, The capsule shell contains cellulose ether.
14. Use of a composition as described in any one of the preceding claims and / or a capsule as described in the preceding claims for achieving at least one of the following effects: i) control weight, ii) reduce appetite, iii) create a feeling of fullness, iv) reduce calorie intake, and v) lower blood sugar spikes.
15. Use of the composition as claimed in the preceding claims, wherein, The composition and / or the capsules shall be taken twice daily before meals.